Performance beauty company Evolus has shipped the first customer orders for Nuceiva (botulinum toxin type A) and launched commercial operations in Great Britain.
“Worldwide, the aesthetics market sector continues to rapidly evolve,” said Evolus president and chief executive David Moatazedi. “We are excited to introduce Nuceiva to Great Britain, the single largest market for aesthetic neurotoxins in the European region, while we continue to finalize plans for entering additional countries as part of a phased rollout.
“Europe is the second largest market for aesthetic neurotoxins globally, and our expansion there will form the foundation for a potential future portfolio of aesthetic products.”
In the UK, Evolus is partnering with a supplier of specialist products to aesthetics practitioners for over 35 years, Wigmore Medical. Evolus plans to introduce Nuceiva next in Germany and Austria in the first half of 2023 and is working closely with its partner, Novvia Pharm. During 2023, the company expects to enter additional European countries, and, subject to regulatory approval, will launch Nuceiva in Australia. The Evolus Innovator and Evolus Early Adopter education programs for healthcare professionals are also underway.
“It’s refreshing to have a new type of aesthetics company to engage with,” said Dr David Eccleston, founder and medical director at MediZen Clinics, and lead investigator for the Nuceiva Post Approval Safety Study (PAS) study. “When I integrate any new treatment into my practice, I look for robust clinical data, exceptional manufacturing and deep expertise. Having options means I can tailor treatments to meet the needs of my patients.”
Dan Stewart, vice president and general manager of Evolus International said: “Starting commercialisation in one of Europe’s biggest aesthetics markets gives practitioners another choice in the neuromodulator they offer to their patients. Our tiered training programs offer credentialed customers the opportunity to learn more about Nuceiva, including the unique aspects of the product and how this translates into results for patients. With support from our distributor partners and pharmacies, we are looking forward to evolving the future of beauty with our customers.”
Nuceiva (botulinum toxin type A) is approved for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) when the severity of the facial lines has an important psychological impact in adults below 65 years of age. The safety and efficacy of Nuceiva were evaluated through the company’s Transparency program, the largest head-to-head pivotal study versus BOTOX to date.
Nuceiva is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events. Reporting forms and information can be found at mhra.gov.uk/yellowcard.
